- Base Value(2025): 79.9 Mn
- Estimated Value(2026): 104.0 Mn
- Forecast Value (2036): 1444.1 Mn
- CAGR (2026 - 2036): 30.1%
Live Biotherapeutic Products & Microbiome CDMO Market Analysis and Forecast by Fact.MR
- The global market for live biotherapeutic products and microbiome CDMO services is estimated to be around US$ 104.0 million in 2026 and has been forecast to expand at a CAGR of 30.1% to end up at US$ 1.4 billion by 2036.
- This market covers contract development and manufacturing services for live biotherapeutic products that use defined microbial strains to treat or prevent disease. Services span strain isolation, fermentation, formulation, fill-finish, and analytical testing under GMP conditions.
- Growth is supported by expanding clinical-stage microbiome therapeutic pipelines, increasing pharmaceutical sponsor demand for specialized CDMO capability, regulatory pathway clarity from FDA and EMA for live biotherapeutics, and the technical complexity of anaerobic manufacturing that limits in-house production for most sponsors.
Summary of Live Biotherapeutic Products & Microbiome CDMO Market
- Market Snapshot
- In 2025, the global Live Biotherapeutic Products & Microbiome CDMO Market was valued at approximately USD 79.9 million.
- The market is estimated to reach USD 104.0 million in 2026 and is projected to attain USD 1.4 billion by 2036.
- The live biotherapeutic products & microbiome cdmo market is likely to expand at a CAGR of 30.1% during the forecast period.
- The market is anticipated to create an absolute dollar opportunity of USD 1.3 billion between 2026 and 2036.
- Antimicrobial Surgical Products accounts for 54% of product share in 2026.
- China (44.9%) and India (42.7%) are the key growth markets during the forecast period.
- Demand and Growth Drivers
- Expanding clinical pipelines of microbiome-based therapeutics across GIoncology, metabolic, and immune-mediated indications are generating growing CDMO demand.
- Pharmaceutical sponsors increasingly outsource live biotherapeutic manufacturing because anaerobic GMP production requires specialized infrastructure not available in conventional CDMO facilities.
- Regulatory pathway clarity from FDA and EMA for live biotherapeutic products is accelerating clinical development activity and associated manufacturing needs.
- Growing investment in microbiome research by pharmaceutical and biotech companies is creating a pipeline of pre-clinical and early clinical programs requiring manufacturing support.
- Increasing demand for defined consortium products containing multiple microbial strains raises manufacturing complexity and favors experienced CDMO partners.
- Product and Segment View
- Antimicrobial Surgical Products accounts for 54% of product share in 2026, supported by consistent demand across primary applications.
- Orthopedic Surgeries accounts for 58% of application share in 2026, supported by consistent demand across primary applications.
- Hospitals accounts for 46% of end use share in 2026, supported by consistent demand across primary applications.
- Key segmentation includes:
- Product: Antimicrobial Surgical Products, Infection Control Consumables, Skin Preparation Products, Wound Care Products
- Application: Orthopedic Surgeries, Cardiovascular Surgeries, General Surgery, Gynecological Surgeries
- End Use: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Research & Academic Institutes
- Technology: Antimicrobial Technology, Barrier Protection Technology, Infection Monitoring Technology, Sterilization Technology
- These systems enable:
- GMP-compliant anaerobic fermentation, formulation, and fill-finish for live microbial therapeutic products
- Strain isolation, characterization, and banking services that support regulatory filing requirements for live biotherapeutic programs
- Analytical method development and quality testing for microbial viability, identity, purity, and potency across product lifecycle stages
- Geography and Competitive Outlook
- Asia Pacific leads growth with China at 44.9%, India at 42.7%, Japan at 36.1%.
- North America shows steady demand with USA at 40.2%.
- European demand remains steady with UK at 38.9%, Germany at 37.6%.
- Other key markets include Brazil at 34.4%.
- Leading participants include Lonza Group Ltd, Arrant Bioscience (Arrant Bio), 4D Pharma plc, Cerbios-Pharma SA, Biose Industrie, Assembly Biosciences, Inc..
- Analyst Opinion
- Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The live biotherapeutic CDMO market is at an inflection point where clinical pipeline expansion is outpacing available manufacturing capacity. Most pharmaceutical sponsors cannot produce live biotherapeutics in-house because anaerobic GMP manufacturing requires specialized equipment, facility design, and operational expertise that differs fundamentally from conventional biologic or small molecule production. This creates a structural outsourcing dynamic where CDMO demand grows in proportion to clinical pipeline activity. Companies with established anaerobic manufacturing infrastructure, regulatory filing experience, and the ability to handle multi-strain consortium products are capturing the highest-value contracts from sponsors advancing programs through clinical development toward commercial launch.'
Key Growth Drivers, Constraints, and Opportunities
Key Factors Driving Growth
- Clinical pipeline expansion across GI, oncology, and immunology indications is creating sustained CDMO demand for live biotherapeutic manufacturing.
- Structural outsourcing dynamic exists because most sponsors lack anaerobic GMP manufacturing capability in-house.
- Regulatory pathway clarity is accelerating clinical development timelines and associated manufacturing procurement.
Key Market Constraints
- Limited number of qualified CDMOs with anaerobic GMP capability creates capacity constraints during peak clinical demand periods.
- Technical complexity of maintaining microbial viability through manufacturing, formulation, and distribution creates quality risk.
- Early-stage nature of many pipeline programs creates revenue uncertainty as clinical attrition reduces the number of programs reaching commercial manufacturing.
Key Opportunity Areas
- First commercial approvals of live biotherapeutic products will create precedent-setting commercial manufacturing demand at scale.
- Multi-strain consortium products create higher-value manufacturing contracts due to increased process complexity and analytical requirements.
- Geographic expansion of CDMO capacity into Asia Pacific creates cost-competitive manufacturing alternatives for global sponsors.
Segment-wise Analysis of the Live Biotherapeutic Products & Microbiome CDMO Market
- Antimicrobial Surgical Products holds 54% of the product segment in 2026.
- Orthopedic Surgeries represents 58% of the application segment in 2026.
- Hospitals accounts for 46% of the end use segment in 2026.
The live biotherapeutic products & microbiome cdmo market is segmented by product, application, end use, technology, and region. Antimicrobial Surgical Products leads by value in the near term, while emerging categories drive the next growth phase.
Which Product Segment Dominates the Live Biotherapeutic Products & Microbiome CDMO Market?
Antimicrobial Surgical Products is expected to account for 54% of the product segment in the global Live Biotherapeutic Products & Microbiome CDMO Market by 2026. Demand is supported by consistent procurement where established performance requirements sustain the installed base.
The segment is expected to maintain its position as capacity expansion and adoption continue. Emerging alternatives are gaining share, but antimicrobial surgical products remains the primary category because of established clinical evidence and buyer familiarity.
Which Application Segment Dominates the Live Biotherapeutic Products & Microbiome CDMO Market?
Orthopedic Surgeries is expected to account for 58% of the application segment in the global Live Biotherapeutic Products & Microbiome CDMO Market by 2026. Demand is supported by consistent procurement where established performance requirements sustain the installed base.
The segment is expected to maintain its position as capacity expansion and adoption continue. Emerging alternatives are gaining share, but orthopedic surgeries remains the primary category because of established clinical evidence and buyer familiarity.
Which End Use Segment Dominates the Live Biotherapeutic Products & Microbiome CDMO Market?
Hospitals is expected to account for 46% of the end use segment in the global Live Biotherapeutic Products & Microbiome CDMO Market by 2026. Demand is supported by consistent procurement where established performance requirements sustain the installed base.
The segment is expected to maintain its position as capacity expansion and adoption continue. Emerging alternatives are gaining share, but hospitals remains the primary category because of established clinical evidence and buyer familiarity.
Which Product Trend is Shaping the Next Phase of Growth in the Live Biotherapeutic Products & Microbiome CDMO Market?
GMP anaerobic fermentation services are gaining share within the live biotherapeutic CDMO market because the majority of clinical-stage microbiome therapeutics contain obligate anaerobic bacterial strains that require oxygen-free manufacturing environments throughout the production process. This technical requirement creates a natural specialization barrier that concentrates manufacturing demand among CDMOs with purpose-built anaerobic infrastructure.
The anaerobic specialization trend reflects the biological reality that most therapeutically relevant gut microbiome organisms cannot survive oxygen exposure during manufacturing. CDMOs that have invested in enclosed anaerobic production suites, oxygen-monitored transfer systems, and validated anaerobic fill-finish capability are positioned to capture the majority of manufacturing contracts as clinical programs advance. This infrastructure investment creates a durable competitive advantage because replicating anaerobic GMP capability requires significant capital and multi-year qualification timelines.
Regional Outlook Across Key Markets
.webp "Top Country Growth Comparison Live Biotherapeutic Products & Microbiome Cdmo Market Cagr (2026 2036)")
- China leads growth at 44.9%, supported by expanding demand and healthcare infrastructure investment.
- The U.S. at 40.2% reflects established demand with technology adoption and regulatory-driven procurement.
- Germany at 37.6% reflects steady European demand supported by healthcare system investment.
CAGR Table
| Country | CAGR (%) |
|---|---|
| China | 44.9% |
| India | 42.7% |
| USA | 40.2% |
| UK | 38.9% |
| Germany | 37.6% |
| Japan | 36.1% |
| Brazil | 34.4% |
Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.
Market Outlook for Live Biotherapeutic Products & Microbiome CDMOs in China
The China live biotherapeutic products & microbiome cdmo market is projected to grow at a CAGR of 44.9% through 2036. Demand is supported by expanding end-use activity and growing adoption of higher-specification products.
- Expanding end-use demand supports procurement across primary applications.
- Infrastructure investment is broadening the installed base.
- Growing performance requirements support mid-range and premium demand.
Demand Trends for Live Biotherapeutic Products & Microbiome CDMOs in India
The India live biotherapeutic products & microbiome cdmo market is projected to grow at a CAGR of 42.7% through 2036. Demand is supported by expanding end-use activity and growing adoption of higher-specification products.
- Expanding end-use demand supports procurement across primary applications.
- Infrastructure investment is broadening the installed base.
- Growing performance requirements support mid-range and premium demand.
Growth Assessment for Live Biotherapeutic Products & Microbiome CDMOs in USA
The USA live biotherapeutic products & microbiome cdmo market is projected to grow at a CAGR of 40.2% through 2036. Demand is supported by expanding end-use activity and growing adoption of higher-specification products.
- Expanding end-use demand supports procurement across primary applications.
- Infrastructure investment is broadening the installed base.
- Growing performance requirements support mid-range and premium demand.
Market Growth Outlook for Live Biotherapeutic Products & Microbiome CDMOs in UK
The UK live biotherapeutic products & microbiome cdmo market is projected to grow at a CAGR of 38.9% through 2036. Demand is supported by expanding end-use activity and growing adoption of higher-specification products.
- Expanding end-use demand supports procurement across primary applications.
- Infrastructure investment is broadening the installed base.
- Growing performance requirements support mid-range and premium demand.
Market Opportunity Outlook for Live Biotherapeutic Products & Microbiome CDMOs in Germany
The Germany live biotherapeutic products & microbiome cdmo market is projected to grow at a CAGR of 37.6% through 2036. Demand is supported by expanding end-use activity and growing adoption of higher-specification products.
- Expanding end-use demand supports procurement across primary applications.
- Infrastructure investment is broadening the installed base.
- Growing performance requirements support mid-range and premium demand.
Demand Analysis for Live Biotherapeutic Products & Microbiome CDMOs in Japan
The Japan live biotherapeutic products & microbiome cdmo market is projected to grow at a CAGR of 36.1% through 2036. Demand is supported by expanding end-use activity and growing adoption of higher-specification products.
- Expanding end-use demand supports procurement across primary applications.
- Infrastructure investment is broadening the installed base.
- Growing performance requirements support mid-range and premium demand.
Growth Forecast for Live Biotherapeutic Products & Microbiome CDMOs in Brazil
The Brazil live biotherapeutic products & microbiome cdmo market is projected to grow at a CAGR of 34.4% through 2036. Demand is supported by expanding end-use activity and growing adoption of higher-specification products.
- Expanding end-use demand supports procurement across primary applications.
- Infrastructure investment is broadening the installed base.
- Growing performance requirements support mid-range and premium demand.
Competitive Benchmarking and Company Positioning
Live Biotherapeutic Products & Microbiome CDMO Market Analysis By Company
- Lonza Group Ltd, Arrant Bioscience (Arrant Bio), 4D Pharma plc, Cerbios-Pharma SA hold strong positions through broad portfolios and established recognition.
- Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd. participate across specific segments and regional channels.
- Technology integration and regulatory expertise create differentiation in premium categories.
The competitive landscape is moderately fragmented. Lonza Group Ltd, Arrant Bioscience (Arrant Bio), 4D Pharma plc, Cerbios-Pharma SA compete through product breadth and technical capability.
Strategic priorities include expanding portfolios, strengthening regulatory positions, and widening distribution.
Key Companies in the Live Biotherapeutic Products & Microbiome CDMO Market
Lonza Group Ltd, Arrant Bioscience (Arrant Bio), 4D Pharma plc, Cerbios-Pharma SA are among the leading players globally.
Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd. hold established positions across specific segments.
NIZO Food Research B.V., Inpac Pharma Co., Ltd. compete through focused offerings.
Recent Industry Developments
- Lonza Group Ltd – Product Portfolio Expansion (2025)
- Lonza Group Ltd expanded its portfolio with new products targeting higher-specification applications.
- Arrant Bioscience (Arrant Bio) – Technology Upgrade Launch (2026)
- Arrant Bioscience (Arrant Bio) introduced upgraded technology across core product lines.
- 4D Pharma plc – Geographic Expansion (2025)
- 4D Pharma plc expanded distribution into high-growth markets.
Leading Companies Shaping the Live Biotherapeutic Products & Microbiome CDMO Market
- Lonza Group Ltd
- Arrant Bioscience (Arrant Bio)
- 4D Pharma plc
- Cerbios-Pharma SA
- Biose Industrie
- Assembly Biosciences, Inc.
- Wacker Chemie AG
- Quay Pharmaceuticals Ltd.
- NIZO Food Research B.V.
- Inpac Pharma Co., Ltd.
Sources and Research References
- Lonza Group Ltd. Product updates and announcements.
- Arrant Bioscience (Arrant Bio). Product updates and announcements.
- 4D Pharma plc. Product updates and announcements.
- Industry publications, government databases, and trade statistics.
- Primary interviews with manufacturers, distributors, and end users.
This bibliography is provided for reader reference and is not exhaustive.
Key Questions This Report Addresses
- What is the current and future size of the Live Biotherapeutic Products & Microbiome CDMO Market?
- How fast is the Live Biotherapeutic Products & Microbiome CDMO Market expected to grow between 2026 and 2036?
- Which product is likely to lead the market by 2026?
- Which application segment is expected to account for the highest demand by 2026?
- What factors are driving demand for this market globally?
- How is technology evolution influencing market growth and product development?
- Which countries are projected to show the fastest growth through 2036?
- What is driving market expansion in China and India?
- Who are the key companies active in the Live Biotherapeutic Products & Microbiome CDMO Market?
- How does Fact.MR estimate and validate the market forecast?
Live Biotherapeutic Products & Microbiome CDMO Market Definition
The live biotherapeutic products and microbiome CDMO market covers contract development and manufacturing services for therapeutic products containing defined live microbial strains. It includes strain development, anaerobic fermentation, formulation, fill-finish, and analytical testing services provided under GMP conditions for pharmaceutical and biotech sponsors.
Live Biotherapeutic Products & Microbiome CDMO Market Inclusions
- The scope covers global and regional forecasts for 2026 to 2036 across product, application, end use, technology, and region.
- It includes regional demand analysis based on end-use activity, regulatory requirements, and technology adoption.
- The report includes pricing and cost analysis across entry-level, mid-range, and premium categories.
- It covers technology trends, drivers, constraints, and the competitive landscape.
Live Biotherapeutic Products & Microbiome CDMO Market Exclusions
- The scope excludes probiotic dietary supplements and food products not classified as regulated pharmaceutical therapeutics.
- It excludes microbiome research tools, sequencing services, and diagnostic products not part of therapeutic manufacturing.
- The report excludes conventional biologic CDMO services for monoclonal antibodies, vaccines, and gene therapies.
- It also excludes fecal microbiota transplant services and autologous microbiome procedures not manufactured as defined pharmaceutical products.
Live Biotherapeutic Products & Microbiome CDMO Market Research Methodology
- The methodology combines secondary research, primary interviews, and forecast modelling.
- It draws on 120+ secondary sources and benchmarks 65+ company portfolios.
- Market sizing covers 30+ countries through a demand-side model with top-down validation.
- Key inputs include end-use activity, regulatory requirements, and technology adoption.
- The model cross-checks demand with shipments, pricing, and product launches.
- Primary validation includes 25+ interviews across manufacturers, distributors, and end users.
- Final estimates go through trade-flow checks and sensitivity testing.
Scope of Analysis
| Parameter | Details |
|---|---|
| Quantitative Units | USD 104.0 million to USD 1.4 billion, at a CAGR of 30.1% |
| Market Definition | Contract development and manufacturing services for live microbial therapeutics including anaerobic fermentation, formulation, and GMP fill-finish. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | China, India, USA, UK, Germany, Japan, Brazil, 30 plus countries |
| Key Companies | Lonza Group Ltd, Arrant Bioscience (Arrant Bio), 4D Pharma plc, Cerbios-Pharma SA, Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., NIZO Food Research B.V., Inpac Pharma Co., Ltd. |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid demand-side and top-down methodology built on country-level demand, product benchmarking, pricing analysis, and primary interviews |
Live Biotherapeutic Products & Microbiome CDMO Market Segmentation
-
Live Biotherapeutic Products & Microbiome CDMO marketSegmented by Product:
- Antimicrobial Surgical Products
- Antimicrobial Sutures
- Triclosan Coated Sutures
- Silver Coated Sutures
- Antimicrobial Drapes
- Disposable Surgical Drapes
- Reinforced Barrier Drapes
- Antimicrobial Sutures
- Infection Control Consumables
- Surgical Gowns
- Disposable Isolation Gowns
- Fluid Resistant Gowns
- Surgical Gloves
- Latex Free Gloves
- Powder Free Sterile Gloves
- Surgical Gowns
- Skin Preparation Products
- Preoperative Solutions
- Chlorhexidine Based Solutions
- Iodine Based Solutions
- Antiseptic Wipes
- Alcohol Based Wipes
- Sterile Skin Prep Pads
- Preoperative Solutions
- Wound Care Products
- Post Surgical Dressings
- Advanced Wound Dressings
- Foam Dressings
- Negative Pressure Systems
- Wound Therapy Devices
- Vacuum Assisted Closure Systems
- Post Surgical Dressings
- Antimicrobial Surgical Products
-
Live Biotherapeutic Products & Microbiome CDMO marketSegmented by Application:
- Orthopedic Surgeries
- Joint Replacement Surgeries
- Knee Replacement Procedures
- Hip Replacement Procedures
- Trauma Surgeries
- Fracture Fixation Procedures
- Bone Reconstruction Surgeries
- Joint Replacement Surgeries
- Cardiovascular Surgeries
- Cardiac Bypass Surgery
- Coronary Artery Bypass Grafting
- Valve Replacement Surgeries
- Vascular Surgeries
- Peripheral Vascular Procedures
- Aneurysm Repair Surgeries
- Cardiac Bypass Surgery
- General Surgery
- Abdominal Surgeries
- Appendectomy Procedures
- Hernia Repair Surgeries
- Gastrointestinal Surgeries
- Bowel Resection Procedures
- Laparoscopic Surgeries
- Abdominal Surgeries
- Gynecological Surgeries
- Cesarean Sections
- High Risk Deliveries
- Emergency C Sections
- Hysterectomy Procedures
- Minimally Invasive Gynecology
- Open Surgical Procedures
- Cesarean Sections
- Orthopedic Surgeries
-
Live Biotherapeutic Products & Microbiome CDMO marketSegmented by End Use:
- Hospitals
- Public Hospitals
- Government Healthcare Hospitals
- Teaching Hospitals
- Private Hospitals
- Multi Specialty Hospitals
- Specialty Surgical Hospitals
- Public Hospitals
- Ambulatory Surgical Centers
- Day Care Surgery Centers
- Outpatient Surgical Units
- Specialty Procedure Centers
- Independent Surgery Clinics
- Private Surgical Clinics
- Minimal Access Surgery Centers
- Day Care Surgery Centers
- Specialty Clinics
- Orthopedic Clinics
- Joint Replacement Centers
- Sports Injury Clinics
- Cardiac Clinics
- Heart Surgery Centers
- Vascular Treatment Clinics
- Orthopedic Clinics
- Research & Academic Institutes
- Medical Universities
- Surgical Training Institutes
- Clinical Research Centers
- Hospital Research Units
- Infection Control Research Labs
- Clinical Trial Units
- Medical Universities
- Hospitals
-
Live Biotherapeutic Products & Microbiome CDMO marketSegmented by Technology:
- Antimicrobial Technology
- Silver Ion Technology
- Silver Coating Systems
- Nano Silver Particles
- Chlorhexidine Technology
- Controlled Release Systems
- Skin Applied Formulations
- Silver Ion Technology
- Barrier Protection Technology
- Microbial Barrier Systems
- Multi Layer Barrier Films
- Hydrophobic Barrier Materials
- Sterile Field Technology
- Operating Room Contamination Control
- Air Flow Sterilization Systems
- Microbial Barrier Systems
- Infection Monitoring Technology
- Digital Infection Tracking
- AI Based Infection Detection
- Post Operative Monitoring Systems
- Sensor Based Systems
- Wound Infection Sensors
- Biomarker Detection Systems
- Digital Infection Tracking
- Sterilization Technology
- Plasma Sterilization
- Low Temperature Plasma Systems
- Gas Plasma Sterilizers
- Radiation Sterilization
- Gamma Radiation Systems
- Electron Beam Sterilization
- Plasma Sterilization
- Antimicrobial Technology
-
Live Biotherapeutic Products & Microbiome CDMO marketSegmented by Formulation:
- Antimicrobial Formulations
- Coated Surgical Products
- Antibiotic Coated Sutures
- Silver Coated Implants
- Topical Antiseptic Formulations
- Skin Prep Liquids
- Sterile Cleaning Solutions
- Coated Surgical Products
- Barrier Formulations
- Film Based Barriers
- Polymer Barrier Films
- Hydrogel Barrier Systems
- Fabric Based Barriers
- Non Woven Surgical Materials
- Reinforced Textile Barriers
- Film Based Barriers
- Wound Care Formulations
- Advanced Dressing Formulations
- Hydrocolloid Dressings
- Foam Based Dressings
- Negative Pressure Formulations
- Vacuum Assisted Therapy Systems
- Absorbent Wound Systems
- Advanced Dressing Formulations
- Sterile Formulations
- Pre Sterilized Products
- Gamma Sterilized Packs
- E Beam Sterilized Products
- Pre Sterilized Products
- Antimicrobial Formulations
-
Live Biotherapeutic Products & Microbiome CDMO marketSegmented by Distribution Channel:
- Direct Sales
- Hospital Procurement
- Large Hospital Contracts
- Government Hospital Supply Chains
- Surgical Procurement Units
- Operating Room Supply Contracts
- Central Sterile Supply Units
- Hospital Procurement
- Distributors
- Medical Device Distributors
- Surgical Equipment Distributors
- Healthcare Supply Distributors
- Regional Distributors
- Hospital Supply Vendors
- Medical Wholesale Suppliers
- Medical Device Distributors
- Retail & Pharmacy Channels
- Hospital Pharmacies
- Inpatient Pharmacy Units
- Outpatient Surgical Pharmacies
- Online Medical Platforms
- Digital Procurement Portals
- E Healthcare Marketplaces
- Hospital Pharmacies
- Institutional Supply Channels
- Government Procurement
- Public Health Tenders
- National Healthcare Programs
- NGO Supply Chains
- Global Health Missions
- Emergency Medical Supply Networks
- Government Procurement
- Direct Sales
-
Live Biotherapeutic Products & Microbiome CDMO marketby Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- North America
- Frequently Asked Questions -
How big is the live biotherapeutic products & microbiome cdmo market in 2025?
The global live biotherapeutic products & microbiome cdmo market is estimated to be valued at USD 79.9 million in 2025.
What will be the size of the live biotherapeutic products & microbiome cdmo market in 2036?
The market size for the live biotherapeutic products & microbiome cdmo market is projected to reach USD 1.4 billion by 2036.
How much will the live biotherapeutic products & microbiome cdmo market grow between 2026 and 2036?
The live biotherapeutic products & microbiome cdmo market is expected to grow at a 30.1% CAGR between 2026 and 2036.
What are the key products in the live biotherapeutic products & microbiome cdmo market?
The key products in the live biotherapeutic products & microbiome cdmo market include Antimicrobial Surgical Products, Infection Control Consumables, Skin Preparation Products, Wound Care Products.
Which segment will contribute the most share in the live biotherapeutic products & microbiome cdmo market in 2026?
In terms of product, Antimicrobial Surgical Products is expected to account for 54% share in the live biotherapeutic products & microbiome cdmo market in 2026.
Which countries are growing fastest in the live biotherapeutic products & microbiome cdmo market?
China (44.9%) and India (42.7%) are the fastest-growing markets during the forecast period.
Who are the key companies in the live biotherapeutic products & microbiome cdmo market?
Key companies in the live biotherapeutic products & microbiome cdmo market include Lonza Group Ltd, Arrant Bioscience (Arrant Bio), 4D Pharma plc, Cerbios-Pharma SA, Biose Industrie, Assembly Biosciences, Inc..
